Associated Papers
CYP genetic polymorphism, and CYP3A inducers and inhibitors regulate apatinib metabolism: Consequences for drug exposure and toxicity risks.
Wang Z et al.
Toxicology and Applied Pharmacology, 2026
Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption.
Schulte J et al.
International Journal of Legal Medicine, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Molecular analysis of the evolutionary history of endometrial and ovarian carcinoma in Lynch syndrome.
Kauppinen AK et al.
International Journal of Cancer, 2025
Genetic variants of cytochrome P450 2C21 identified by screening 6344 dogs influenced oxidations of the probe drug omeprazole.
Uno Y et al.
Biochemical Pharmacology, 2025
Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer.
Cao J et al.
Journal of Chemotherapy (florence, Italy), 2025
An Investigational Study on the Role of ADME Agents' Genetic Variation on DD217 Pharmacokinetics and Safety Profile.
Sychev DA et al.
Pharmaceuticals (basel, Switzerland), 2025
The Genetic Polymorphisms of CYP2C9 and VKORC1 in the Saudi Population and Their Impact on Anticoagulant Management.
Al Hamad M
Medicina (kaunas, Lithuania), 2025
The role of genetic polymorphisms on drug response in Alzheimer's disease: a systematic review.
Climacosa FMM et al.
Bmc Medical Genomics, 2025
Pharmacogenetics and Molecular Ancestry of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Ecuadorian Subjects with Type 2 Diabetes Mellitus.
Ortega-Ayala A et al.
Pharmaceuticals (basel, Switzerland), 2025
Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review.
Gerstman MD et al.
British Journal of Anaesthesia, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The Role of Pharmacogenetic Biomarkers in Pain.
Martin da Silva I et al.
Biomedicines, 2025
Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes-Pharmacogenomic Impact on Inter-Organ Communication.
Figueiral M et al.
Comprehensive Physiology, 2025
Modeling the Influence of CYP2C9 and ABCB1 Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Losartan.
Babaev D et al.
Pharmaceutics, 2025
Genetic Mutations and Small Bowel Ulcerating Disease: Role in Diagnosis?
Modi R et al.
Current Gastroenterology Reports, 2025
Molecular Ancestry Across Allelic Variants of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Mexican-Mestizo DMT2 Patients.
Ortega-Ayala A et al.
Biomedicines, 2025
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas.
Wolthuis DFGJ et al.
European Journal of Human Genetics : Ejhg, 2025
Analgesic therapy failure in a COMT HPS/HPS diplotype carrier heterozygous for the CYP2D6 *4 allele with fibromyalgia-a case report.
Bollinger A et al.
Pain Reports, 2025
Frequencies of CYP2C9 polymorphisms in a Syrian cohort.
Aldiban W et al.
Bmc Genomics, 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro.
Bao SS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Pharmacogenetics polygenic response score predicts outcomes in aspirin-treated stroke patients.
Ma RN et al.
Frontiers in Pharmacology, 2025
The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients.
Jokhab S et al.
Frontiers in Pharmacology, 2025
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants.
Babaev D et al.
Frontiers in Systems Biology, 2025
Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications.
Alvarado AT et al.
Frontiers in Pharmacology, 2025
Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB.
Acosta-Monterrosa AA et al.
Frontiers in Pharmacology, 2025
Prevalence of risk phenotypes associated with CYP2C9*2, *3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice.
Biswas M et al.
Frontiers in Pharmacology, 2025
A digital twin of glimepiride for personalized and stratified diabetes treatment.
Elias M et al.
Frontiers in Pharmacology, 2025
Application of rapid genotyping of Warfarin individualized pharmacogenetic variants in Warfarin therapy.
Huang D et al.
Scientific Reports, 2024
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R et al.
Jama Network Open, 2024
Influence of CYP2C9 phenotypes on phenytoin plasma concentration in neurosurgical Brazilian patients.
Kurtz P et al.
Pharmacogenetics and Genomics, 2024
Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation.
Shi K et al.
Pharmacogenetics and Genomics, 2024
Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.
Parikh SJ et al.
Journal of Inorganic Biochemistry, 2024
Investigating the Correlation between Genotypes and Hepatic Protein Expression of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 Using Postmortem Tissue from a Danish Population.
Pedersen KW et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Establishing national reference materials for genetic testing of cytochrome P450.
Jia Z et al.
Pharmacogenetics and Genomics, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs.
Manson LEN et al.
European Journal of Human Genetics : Ejhg, 2024
Phenotype-Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism.
Böhm R et al.
Clinical Pharmacology and Therapeutics, 2024
Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients.
Zhang S et al.
Pharmacogenetics and Genomics, 2024
Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens.
Lusiki Z et al.
Omics : a Journal of Integrative Biology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Stability of Anticoagulation Following Acenocoumarin in Stroke Patients: Role of Pharmacogenomics and Acquired Factors.
Dubey AK et al.
Annals of Indian Academy of Neurology, 2024
A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.
Geng K et al.
Cpt: Pharmacometrics & Systems Pharmacology, 2024
Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease.
Drent M et al.
Drug Safety, 2024
Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients.
Oscanoa TJ et al.
British Journal of Clinical Pharmacology, 2024
Genetic variation of CYP2C9 gene and its correlation with cardiovascular disease risk factors.
Rasool GS et al.
Molecular Biology Reports, 2024
New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model.
Rodríguez-Fernández K et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2024
Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach.
Avsar O
Nucleosides, Nucleotides & Nucleic Acids, 2024